文献速递肝病

北美严重特异质性药物性肝损伤的长期趋势:急性肝衰竭研究组注册中心更新

Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry.
PubMed 文献 · Am J Gastroenterol · 2022-01-01

基于急性肝衰竭研究组注册中心2332例成人急性肝衰竭患者,277例(11.9%)被专家判定为特异质性药物性肝损伤相关急性肝衰竭(INR≥1.5且伴肝性脑病)。比较1998至2008年(155例)与2008至2018年(122例)两个时期,发现草药/膳食补充剂所致病例比例从9.7%升至22%(P<0.01),抗菌药物所致比例从45.8%降至38.5%(P=0.03),无移植生存率从23.5%升至38.7%(P<0.01),接受肝移植患者比例从46.4%降至33.6%(P<0.03)。

要点

  • 草药/膳食补充剂所致药物性肝损伤相关急性肝衰竭比例从9.7%升至22%(P<0.01)。
  • 抗菌药物所致比例从45.8%降至38.5%(P=0.03)。
  • 无移植生存率从23.5%升至38.7%,接受肝移植比例从46.4%降至33.6%。

核心结论

  • 北美药物性肝损伤相关急性肝衰竭的病因构成在演变,草药/膳食补充剂病例比例上升,其他可疑药物类别比例下降。
  • 无移植生存率显著提高且肝移植需求减少的原因尚不明确,可能归因于重症监护改善、N-乙酰半胱氨酸使用增加及患者预后判断改善。

研究设计与样本

  • 基于急性肝衰竭研究组注册中心的前瞻性队列研究,纳入2332例急性肝衰竭患者,其中277例(11.9%)经专家判定为特异质性药物性肝损伤相关急性肝衰竭(INR≥1.5且伴肝性脑病)。
  • 比较1998年1月20日至2008年1月20日期间155例与2008年1月21日至2018年1月20日期间122例两个时期的病例。

主要发现

  • 277例中涉及97种单一或联合药物:抗菌药物118例(43%)、草药/膳食补充剂42例(15%)、中枢神经系统药物/非法物质37例(13%)、肿瘤/生物制剂29例(10%)、其他51例(18%)。
  • 草药/膳食补充剂所致药物性肝损伤相关急性肝衰竭比例从9.7%升至22%(P<0.01)。
  • 抗菌药物所致比例从45.8%降至38.5%(P=0.03)。
  • 无移植生存率从23.5%升至38.7%(P<0.01),接受肝移植患者比例从46.4%降至33.6%(P<0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Idiosyncratic drug-induced liver injury (DILI) is the second leading cause of acute liver failure (ALF) in the United States. Our study aims were to characterize secular trends in the implicated agents, clinical features, and outcomes of adults with DILI ALF over a 20-year period. METHODS: Among 2,332 patients with ALF enrolled in the ALF Study Group registry, 277 (11.9%) were adjudicated as idiosyncratic DILI ALF (INR ≥ 1.5 and hepatic encephalopathy) through expert opinion. The 155 cases in era 1 (January 20, 1998-January 20, 2008) were compared with the 122 cases in era 2 (January 21, 2008-January 20, 2018). RESULTS: Among 277 cases of DILI ALF, 97 different agents, alone or in combination, were implicated: antimicrobials, n = 118 (43%); herbal/dietary supplements (HDS), n = 42 (15%); central nervous system agents/illicit substances, n = 37 (13%); oncologic/biologic agents, n = 29 (10%); and other, n = 51 (18%). Significant trends over time included (i) an increase in HDS DILI ALF (9.7% vs 22%, P < 0.01) and decrease in antimicrobial-induced DILI ALF (45.8% vs. 38.5%, P = 0.03) and (ii) improved overall transplant-free survival (23.5%-38.7%, P < 0.01) while the number of patients transplanted declined (46.4% vs 33.6%, P < 0.03). DISCUSSION: DILI ALF in North America is evolving, with HDS cases rising and other categories of suspect drugs declining. The reasons for a significant increase in transplant-free survival and reduced need for liver transplantation over time remain unclear but may be due to improvements in critical care, increased NAC utilization, and improved patient prognostication.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Rao A, Rule JA, Hameed B, et al. Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry. Am J Gastroenterol. 2022. PMID: 35081550. doi:10.14309/ajg.0000000000001655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。